H eart failure is the end result of cardiovascular disease states, such as hypertension and myocardial ischemia. 1 Heart failure is characterized by abundant accumulation of matrix proteins in the extracellular space. Among the extracellular matrix (ECM) proteins, collagens constitute up to 85%. 2, 3 Collagens are proteins that consist of a triple helix of polypeptide chains and globular domains, and comprise a family of proteins of at least 19 genetically distinct types, among which type I and type III constitute two-thirds. 2, 3 Collagen type I is usually present in the form of thick fiber with a high tensile strength. Therefore, collagen type I content is considered a major determinant of myocardial stiffness. 3, 4 Fibroblasts are the major source of collagen in the myocardium. 3, 5 Proliferation of cardiac fibroblasts and deposition of collagen are directly associated with both systolic and diastolic (especially the latter) heart failure. 6 Collagen type I accumulation in the heart depends not only on its production, but also on its degradation, which is performed by proteinases, such as matrix metalloproteinase-1 (MMP-1). 3 Activation of the renin-angiotensin system with synthesis and release of angiotensin II (Ang II) is a key feature of hypertension and myocardial ischemia, and both conditions lead to cardiac remodeling comprising myocyte hypertrophy and fibroblast proliferation. 7, 8 Most of the known effects of Ang II in the heart are believed to be mediated by the activation of its type 1 (AT 1 ) receptors. 8 AT 1 receptors are widely present on cardiac fibroblasts, and Ang II via AT 1 activation mediates fibroblast proliferation and ECM production. 9, 10 Indeed, long-term intravenous infusion of Ang II is associated with the development of hypertension and cardiac fibrosis. 10, 11 In recent studies, we showed that Ang II via AT 1 activation stimulates oxidative stress in human coronary artery endothelial cells. 12 Whether inhibition of oxidative stress can modulate the profibrotic effects of Ang II is not known.
Peroxisome proliferator-activated receptors (PPAR) are a family of at least 3 nuclear receptors (␣, ␤/␦, and ␥). 13, 14 After activation by the ligand, PPARs heterodimerize with retinoic X receptor and recognize PPAR response element which exists in the promoter of target genes. 15 The ligand-activated PPAR functions as a transcription factor and regulates target gene expression. It has been shown that PPAR plays a critical role in lipid catabolism, peroxisome proliferation, 13 and adipogenesis. 16 Several investigators have shown that PPAR-␥ ligands reduce myocardial infarct size after coronary artery ligation. 17, 18 Shiomi et al 19 provided evidence that pioglitazone attenuates cardiac remodeling after chronic ischemia. In recent studies, we showed that the PPAR-␥ ligand pioglitazone blocks the effect of several mediators of tissue injury, such as oxidized low density lipoprotein (ox-LDL), Ang II, and tumor necrosis factor-␣ (TNF-␣), on endothelial cells. 12 In the present study, we examined the hypothesis that pioglitazone blocks the effect of Ang II on collagen type I and MMP-1 expression in cardiac fibroblasts as a basis of its effect on cardiac remodeling.
Materials and Methods

Cell Culture
Rat cardiac fibroblasts were prepared and cultured as described earlier. 20 In brief, rat hearts were removed from anesthetized Sprague-Dawley male rats (200 to 250 g, Jackson Laboratories, Bar Harbor, ME). The ventricles were isolated, minced, and digested in 0.25% collagenase solution (37°C, 1 hour). After digestion, the cells were pelleted and suspended in Dulbecco's modified Eagle's medium (DMEM) supplemented with 1% penicillin and streptomycin and 10% fetal bovine serum (FBS). The suspension was transferred to 56.7 cm 2 dishes (Nuncbrand). After a 60-minute incubation period, cells that were weakly attached or unattached were removed, and the attached cells were grown to confluence. After 2 to 3 days, the confluent cells were detached by trypsin and seeded on new dishes. The purity of these cultured cardiac fibroblasts was greater than 95% on the basis of positive staining for vimentin and negative staining for smooth muscle actin and von Willebrand factor (vWF, Sigma). Third to fifth passage cardiac fibroblasts were used for all experiments. Cardiac fibroblasts were treated with different concentrations of Ang II (10 Ϫ8 , 10 Ϫ7 , and 10 Ϫ6 M) for 6 to 24 hours to determine the expression of collagen type I and MMP-1.
In parallel experiments, cells were pretreated with pioglitazone (10 mol/L) for 30 minutes followed by treatment with Ang II (or left untreated) in the presence of pioglitazone. This concentration of pioglitazone in previous studies was shown to result in maximal inhibition of reactive oxygen species (ROS) release. 12 In other experiments, fibroblasts were pretreated with trolox (10 mol/L), a water soluble analog of vitamin E, before exposure to Ang II.
All experimental procedures were performed in accordance with protocols approved by the Institutional Animal Care and Use Committee.
Measurement of Intracellular Generation of Reactive Oxygen Species
Intracellular ROS generation was measured by the method described by Ushio-Fukai et al. 21 In brief, cardiac fibroblasts were cultured with DMEM containing 10% calf serum until they grew to 60% confluence; then they were cultured in DMEM containing 0.1% calf serum for 48 hours. Cells were then treated with Ang II (10 Ϫ7 M) for 12 hours, and the ROS-sensitive fluorophore DCF-DA (10 mol/L) added. Intracellular ROS generation was measured using Fluoromax-3 spectrofluorimeter with an excitation set at 485 nm and emission at 530 nm. This method involves conversion of the nonfluorescent dichlorofluorescein diacetate to the highly fluorescent compound 2,7-dichlorofluorescein (DCF) in the cells. In parallel studies, cells were pretreated with pioglitazone for 12 hours followed by treatment with Ang II or left untreated.
Collagen Synthesis Assay
Collagen synthesis was determined by measuring 3 H-proline incorporation as described earlier. 22 In brief, cardiac fibroblasts were made quiescent by culture in serum-free DMEM for 48 hours. These cells were then cultured in DMEM supplemented with 2.5% FBS, 50 g/mL ascorbate and L- [2,3,4,5- 3 H] proline (1 Ci/mL, Amershan Biosciences) and treated as mentioned above. After treatment, cells were washed with PBS and ice-cold 10% trichloroacetic acid (TCA). The cells were solubilized and the cell extracts analyzed in a liquid scintillation counter. The count represented the amount of newly synthesized collagen. The data were normalized to cell number.
Protein Preparation and Analysis by Western Blot
Fibroblasts from each group were pelleted and extracted in iced cell lysis buffer (Cell Signaling Technologies). Cell lysates were centrifuged at 15 000g for 15 minutes at 4°C and the supernatants from each group (45 g protein per lane) were separated by 10% SDS-PAGE (for MMP-1) and 8% nondenatured-PAGE (for collagen type I) and then transferred to nitrocellulose membranes. After incubation in blocking solution (5% nonfat milk, Sigma), membranes were incubated with primary antibodies overnight at 4°C. Primary antibodies used were anticollagen type I (Rockland) and anti-MMP-1 (Oncogene). Membranes were washed with 1ϫTBST solution and then incubated with secondary antibody (1:5000 dilution, Amersham Life Sciences) for 2 hours. The membranes were detected with the ECL system (Amersham Life Sciences) and relative intensities of protein bands analyzed by Scan-gel-it software. 23 
Collagenase Activity Assay
Collagenase zymography was performed as recently described. 24 Essentially, the conditioned culture medium was collected from the dishes and 10 L of the medium was subjected to electrophoresis in SDS polyacrylamide gel containing 0.1% gelatin under nonreducing conditions. The gels were soaked in 2.5% Triton-X100 for 60 minutes and then washed with water for 60 minutes to remove SDS. The gels were then incubated in a developing buffer containing 50-mmol/L Tris, pH 7.4, 5-mmol/L CaCl 2 , and 0.02% sodium azide for 18 hours at 37°C. After incubation, the gels were stained with Coomassie blue and photographed.
Electrophoresis Mobility Shift Assay
Nuclear extracts were prepared according to the method published previously. 25 In brief, cultured cells were washed with ice-cold Tris-buffered saline twice and pelleted. Then the pellets were suspended in 400 L of solution A (10 mmol/L HEPES, 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.1 mmol/L EGTA, 1 mmol/L dTT, 1 mmol/L PMSF, 1 mmol/L leupeptin, pH 7.9) for 5 minutes. After a brief vortex and centrifugation, the pellets were suspended and incubated in 150 L of solution B (20 mmol/L HEPES, 0.4 mol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L dTT, 1 mmol/L PMSF, 1 mmol/L leupeptin) for 30 minutes. After centrifugation, the supernatants were transferred to a clear tube and stored in Ϫ80°C. EMSA was performed as described previously. In brief, 10 g of nuclear extract was incubated with radio-labeled probes for 30 minutes. The probes used were oligonucleotides containing nuclear factor-B (NF-B) binding sites (5Ј-AGT TGA GGG GAC TTT CCC AGG C-3Ј, 3Ј-TCA ACT CCC CTG AAA GGG TCC G-5Ј) or activator protein-1(AP-1) binding sites (5Ј-CGC TTG ATG AGT CAG CCG GAA-3Ј, 3Ј-GCG AAC TAC TCA GTC GGC CTT-5Ј).
The protein/DNA complexes were separated by 4% acrylamide gel. After autoradiography, the relative intensities of bands were analyzed by Scan-gel-it software. 23 
Data Analysis
All data represent the mean of duplicate samples from at least 3 separately performed experiments. Data are presented as meanϮSD. Statistical significance was determined in multiple comparisons among independent groups of data using ANOVA followed by F-test. A probability value of Յ0.05 was considered significant.
Results
Ang II and the Expression of Collagen Type I and MMP-1 in Cardiac Fibroblasts
Ang II treatment increased the expression of collagen type I protein in a time-and concentration-dependant fashion in cardiac fibroblasts (Figure 1) . Concurrent with the increase in collagen expression, MMP-1 expression decreased (PϽ0.01 versus control). This effect, ie, reduction in MMP-1, was evident when cells were treated with Ang II for as short a period of time as 6 hours (Figure 2 left) . In all subsequent experiments, the concentration of Ang II was kept at 10 Ϫ7 M and incubation time at 12 hours.
Next we examined if the effect of Ang II on MMP expression was associated with change in MMP activity. We noted a significant reduction in MMP activity in cardiac fibroblasts when the cells were treated with Ang II (both PϽ0.05) (Figure  2 , right). There were 2 distinct bands on zymography, a 62 kDa band, reflecting MMP-2, and another 42 kDa band reflecting MMP-1. The latter band was quite faint and the signal was only one-third to one-half of the MMP-2 band. Nonetheless, signals for both MMP-1 and MMP-2 fell further on treatment of cardiac fibroblasts with Ang II.
Modulation of Ang II-Induced Expression of Collagen Type I and MMP-1 by Pioglitazone
As mentioned above, Ang II treatment markedly increased the expression of collagen and decreased the expression of MMP. These effects of Ang II were almost completely blocked by the pretreatment of cardiac fibroblasts with pioglitazone (both PϽ0.05 versus Ang II treatment). Pioglitazone pretreatment also reversed the effect of Ang II on MMP activity in fibroblasts. Notably, pioglitazone alone had no effect on the basal expression level of collagen or MMP expression (Figure 3) .
Modulation of Ang II-Induced Collagen Synthesis by Pioglitazone
Compared with control, Ang II treatment (10 Ϫ7 M, 12 hours) enhanced collagen synthesis in cardiac fibroblasts (PϽ0.01). Pretreatment of cells with pioglitazone attenuated this effect of Ang II (PϽ0.05 versus Ang II treatment). Notably, pioglitazone alone had no effect on basal collagen synthesis (Figure 4 ). 
Ang II-Induced ROS Generation in Cardiac Fibroblasts and Modulation by Pioglitazone
There was minimal ROS generation in cardiac fibroblasts in the control state. However, on treatment with Ang II, there was a marked increase in intracellular production of ROS, which was inhibited by pretreatment of cardiac fibroblasts with pioglitazone. Pioglitazone alone had no effect on basal ROS generation. Results of a representative experiment, as well as summary of data from multiple experiments are shown in Figure 5 .
To determine whether a known antioxidant would alter the effects of Ang II, fibroblasts were treated with trolox before exposure to Ang II. As shown in Figure 6 , trolox pretreatment significantly blocked the effect of Ang II on collagen type I and MMP-1 expression. These effects of trolox and pioglitazone were qualitatively similar.
Pioglitazone and Ang II-Induced Activation of NF-B and AP-1 in Cardiac Fibroblasts
Ang II treatment significantly enhanced the activation of transcription factor NF-B (PϽ0.05 versus control). This effect of Ang II was blocked by the pretreatment of cardiac fibroblasts with pioglitazone (PϽ0.05 versus no pretreatment).
Ang II treatment also significantly induced the activation of another transcription factor AP-1 (PϽ0.05 versus control), but this effect was not modulated by the pretreatment of cells with pioglitazone. Pioglitazone alone had no effect on the basal activation of either NF-B or AP-1 ( Figure 7 ).
Discussion
In this study, we show that Ang II increases the expression and synthesis of collagen type I in cardiac fibroblasts.
Concurrently, Ang II decreases MMP-1 expression and activity. Importantly, we show that the PPAR-␥ ligand pioglitazone almost completely blocks these effects of Ang II. We also show a marked increase in ROS release when fibroblasts are exposed to Ang II, and pioglitazone reduces Ang IIinduced ROS generation. Lastly, we show that Ang II activates the transcription factors NF-B and AP-1, but pioglitazone pretreatment only inhibits the activation of NF-B.
Effect of Ang II on Collagen Synthesis and Degradation
Studies in rat and human cardiac fibroblasts have shown that Ang II stimulates cell proliferation and collagen synthesis. 26 -29 The increase in synthesis and expression of collagen in response to Ang II in cardiac fibroblasts was confirmed in the present study. Because collagen content of ECM depends not only on its production, but also on its degradation, which relies on enzymes such as MMP-1, 3 we conducted studies to determine the expression of MMP-1. We found that Ang II decreased the expression of MMP-1, even when cardiac fibroblasts were incubated with Ang II for a short period of time (6 hours). The 10 Ϫ7 M concentration of Ang II, which is likely to be present in the ischemic heart, significantly inhibited MMP-1 expression. Importantly, collagenase activity was reduced by the treatment of fibroblasts with Ang II in concert with a decrease in its protein expression. It is logical to assume that the reduction in collagenase activity would result in less collagen degradation. This may well be the explanation for the profibrotic effect of Ang II in the myocardium in hypertension, as well as during chronic ischemia, when the renin-angiotensin-system is activated. A comment needs to be made regarding the identification of MMP-1 and MMP-2 on zymography here. The signal for MMP-1 was considerably weaker than that for MMP-2, but there was a consistent reduction in both signals when fibroblasts were treated with Ang II, and pioglitazone pretreatment reversed the effects of Ang II. We were guided in the detection and recognition of MMP-1 and MMP-2 bands by the work of Yu et al 28 and Watanabe et al. 29 Brilla et al 30 in 1994 first showed that Ang II decreases collagenase activity in cardiac fibroblasts. This effect of Ang II could be blocked by the AT 1 receptor antagonist losartan. More recently, Peng et al 31 showed that Ang II decreases TNF-␣-stimulated MMP-2 activity and increases the expression of MMP inhibitor (TIMP-1) in neonatal rat cardiac fibroblasts. These effects of Ang II on cardiac fibroblasts are different from the effects of Ang II in endothelial cells 32 and cardiac myocytes, 33, 34 wherein Ang II enhances MMP expression/activity. Thus, Ang II may affect MMP expression and activity differently in different cell types. Nonetheless, its effects on fibroblasts tend to favor collagen synthesis.
Ang II-Induced Oxidative Stress and the Modulatory Effect of Pioglitazone
NADPH oxidase is a major source of ROS in vascular and cardiac tissues, and Ang II stimulates NADPH oxidase. 35 It has been postulated that the increase in ROS is an important mechanism by which Ang II contributes to the pathogenesis of vascular disease, 36, 37 and perhaps cardiac remodeling. Sano et al 38 showed that Ang II stimulates ROS generation in cardiac fibroblasts, and we confirmed this phenomenon in the present study. In another recent study, 12 we observed that pioglitazone blocks ROS generation in response to ox-LDL, TNF-␣, and Ang II in human coronary artery endothelial cells. Several investigators have shown that pioglitazone attenuates the expression and activity of NAD(P)H oxidase subunits (p22phox, p47phox, gp91phox). 39, 40 We postulate that Ang II induces ROS generation in cardiac fibroblasts by activating NADPH oxidase and possibly other pathways, but this remains to be defined. Nonetheless, we observed that pioglitazone attenuated Ang II-enhanced ROS generation. In parallel experiments, pioglitazone modulated the effect of Ang II on collagen as well as MMP-1 expression in cardiac fibroblasts. We suggest that the inhibition of ROS generation is, in large part, the basis of the observed effects of pioglitazone. The evidence for this suggestion comes from experiments wherein fibroblasts were pretreated with trolox. This water soluble analog of vitamin E exerted qualitatively similar effects as pioglitazone on collagen type I and MMP-1 expression in response to Ang II.
Many cytokines can transduce intracellular signals that stimulate the proteolytic breakdown of IB␣, a cytoplasmic inhibitor of transcription factor NF-B. 41, 42 In turn, NF-B is rapidly translocated to the nucleus, where it regulates the expression of many related genes. NF-B is a redox-sensitive transcription factor, which is usually activated by oxidative stress. 43 We have previously shown that NF-B is involved in the activation of endothelial cells in response to Ang II through increased intracellular oxidative stress. 12 Now, we show that Ang II activates NF-B in cardiac fibroblasts. It was the activation of NF-B, which was blocked by the pretreatment of cells with pioglitazone. This observation, together with the data on the measurement of ROS generation, suggests that oxidative stress is one of the important mediators of the effects of Ang II on cardiac fibroblasts, and pioglitazone attenuates the effects of Ang II by blocking ROS release and related transcription factor activation.
In addition to NF-B, we showed the activation of AP-1 in response to Ang II. In at least one previous study, 34 activation of AP-1 by Ang II in cardiac tissues was described, although it is not clear if the preparation contained fibroblasts. Hattori et al 44 showed that Ang II activates AP-1 in vascular smooth muscle cells, and this effect is not affected by pioglitazone. In our study in pure cardiac fibroblasts, we observed that Ang II stimulated the activation of AP-1, and pioglitazone pretreatment did not modulate this effect of Ang II. Schenk et al 45 found that transient expression or exogenous application of thioredoxin (an important cellular protein oxidoreductase with antioxidant activity) resulted in a dose-dependent inhibition of NF-B activity. AP-1-dependent transactivation, in contrast, was strongly enhanced by thioredoxin. As such, a possible explanation for the lack of effect on AP-1 is that pioglitazone inhibits the ROS production induced by Ang II not only by enhancing antioxidant capacity of cells, but also by its own antioxidant effect.
Perspectives
This study shows that Ang II stimulates collagen synthesis and activity, and attenuates the expression of collagendegrading enzyme MMP-1 in rat cardiac fibroblasts. We propose that these effects of Ang II are mediated, in large part, by Ang II-stimulated ROS generation. Because the hemodynamic stress of hypertension can be excluded in the present in vitro studies, it can be safely assumed that it is the presence of Ang II (and associated ROS generation) that is the basis of enhanced collagen synthesis by cardiac fibroblasts. Importantly, modulation of the effects of Ang II in cardiac fibroblasts by pioglitazone may have important therapeutic implications in disease states characterized by enhanced collagen synthesis in the heart.
